Since 2010, Manzuri Law has worked alongside California’s cannabis industry through every stage of legalization and regulatory evolution — from early medical collectives and DEA enforcement activity to municipal cannabis ordinances, California’s statewide licensing rollout, and the transition into the modern dual-use marketplace.
One thing we have learned over years of “boots on the ground” cannabis regulation is this:
Cannabis laws rarely evolve in a straight line.
The April 2026 federal rescheduling framework may ultimately become one of the most transformative developments in modern cannabis law, but operators should understand that the legal framework is still developing rapidly and will almost certainly evolve repeatedly over the coming months and years.
At this stage, the federal government has created the outline of a federal framework that recognizes state-licensed medical marijuana operators — not a fully operational national cannabis market.
And for California operators in particular, that distinction matters enormously.
California’s cannabis market was built around an integrated dual-use model in which many businesses operate medical and adult-use activities under the same ownership structure, facilities, personnel, and supply chains. The emerging federal framework recognizes certain state-licensed medical marijuana activity while continuing to prohibit adult-use cannabis at the federal level, creating significant uncertainty for California operators.
Among the key unanswered questions are whether medical and adult-use operations will ultimately need to be separated, how federal registration requirements will interact with California’s dual-designation licensing structure, what disclosures and compliance obligations federally registered operators may face, and whether participation in the emerging federal medical framework will create strategic advantages—or additional regulatory burdens—for certain businesses. These issues will likely influence licensing decisions, operational planning, investment strategies, and long-term market positioning throughout California’s cannabis industry.
I. The April 2026 Rescheduling Action: What the Rule Actually Does
In April 2026, the federal DOJ issued a final order moving certain marijuana-related products into Schedule III under the Controlled Substances Act (“CSA”). In effect, this means that operators dealing with eligible categories of marijuana products may apply for DEA registration, and that commercial activities conducted in compliance with federal rules will no longer be classified as illicit Schedule I activity.
The rule recognizes two categories of marijuana products that are eligible for federal registration:
- FDA-approved marijuana-derived drug products; and
- Marijuana products produced under qualifying state medical marijuana programs.
This is a significant federal shift because marijuana is no longer being treated uniformly as Schedule I contraband in every context.
However, adult-use cannabis remains federally prohibited Schedule I activity, for which there is still no pathway for federal registration or compliance. However, a separate administrative hearing process, set to commence on June 29, 2026, will consider whether adult-use marijuana should also be moved from Schedule I to Schedule III.
That means, pending the outcome of the hearing process, California operators are now navigating a split system:
- A federally recognized medical marijuana framework; and
- A still federally prohibited adult-use cannabis market.
A. The DEA Registration Framework
The new framework is built around DEA registration under 21 CFR Part 1301.
DEA has now opened registration pathways for qualifying state medical marijuana businesses, including:
- Cultivators/bulk manufacturers,
- Manufacturers,
- Distributors,
- Dispensers, and
- Laboratories.
Registration is activity-specific, meaning operators may require separate registrations depending on whether they cultivate, manufacture, distribute, export, test, or dispense cannabis products. Separate registrations may also ultimately be required by premises, activity type, or operational structure.
Importantly, the rule does not create an entirely new standalone cannabis regulatory system. Rather, it layers qualifying state medical marijuana businesses into the existing DEA controlled-substance registration framework governed by Part 1301.
The framework heavily defers to state medical marijuana systems. The rule treats state medical licensure as strong evidence of authorization, and the DEA Administrator generally must grant registration unless doing so would be inconsistent with public-interest factors under 21 U.S.C. § 823 or applicable treaty obligations.
Importantly, the rule creates an expedited filing window, whereby applications submitted within 60-days following publication of the rule shall be reviewed within 6-months. Based on the current publication timeline, the expedited filing deadline would fall in late June 2026. Applicants that file an application within this window may engage in the manufacture, distribution, and/or dispensing of marijuana for medical purposes in compliance with state medical laws while applications are reviewed.
Many operators have referred to this as a form of “6-month immunity,” although that phrase should be used carefully.
The 60-day period refers to the filing window for expedited review. The operational protections during application pendency may extend substantially longer depending on DEA review timing, but the framework does not create blanket immunity from federal law. Rather, the protection applies specifically to qualifying medical marijuana activities operating within the registration framework while applications remain under review.
Importantly, the expedited filing window creates a strategic timing issue for operators. Businesses are currently being asked to evaluate potentially transformative operational decisions while significant legal and regulatory questions remain unresolved — including supply-chain restrictions, interstate commerce implications, DEA application disclosures, FDA/FDCA exposure, and the practical mechanics of operating a federally recognized medical business inside California’s integrated adult-use market.
That tension is one reason many operators are currently focusing on strategic planning that preserves optionality, rather than making immediate irreversible operational commitments before additional federal guidance and hearings occur.
II. California’s Biggest Unknown: Commingled Adult and Medical Use Licensees May Need to Segregate Operations
One of the biggest misconceptions we are seeing is the assumption that rescheduling means cannabis is now “federally legal.” The federal framework currently recognizes only qualifying medical marijuana activity operating within the DEA registration system. Accordingly, adult-use and recreational cannabis activity remain federally prohibited Schedule I activity under the Controlled Substances Act.
Under 21 CFR 1301.13(k):
- Cultivators/manufacturers may transfer only to registered manufacturers or distributors;
- Distributors may transfer only to registered distributors or dispensers; and
- Dispensers may dispense only to qualified medical patients.
That distinction becomes operationally important because the federal framework creates what appears to be a closed-loop medical supply chain.
Compared to strictly medical states, California presents a unique complication because the state operates a highly integrated dual-use system, whereby individual operators may simultaneously operate pursuant to both an adult-use (A-) and medicinal-use (M-) license designation.
As a result, many California cannabis businesses are structured around:
- Combined adult-use and medical licensing,
- Integrated supply chains,
- Vertically integrated operations,
- And commingled inventory systems.
The federal framework does not clearly explain how the federal government will treat such commingled operations, which creates potential risk for California operators with both A and M designations.
However, if 21 CFR 1301.13(k) is interpreted and enforced according to its plain language, federally registered operators may only transact with other federally registered operators.
Under that reading, several major operational consequences immediately follow:
- A federally registered cultivator likely could not lawfully supply a non-registered California distributor;
- A federally registered distributor likely could not continue servicing adult-use dispensaries using federally registered inventory;
- Commingled medical/adult-use inventory systems may become difficult or impossible to maintain; and
- Businesses operating in California’s integrated dual-use market may ultimately require meaningful segregation between federally recognized medical operations and state adult-use operations.
This creates what may become one of the defining operational questions of the rescheduling era:
At what point in the supply chain does cannabis become “medical” versus “adult-use”?
Some interpretations place that distinction downstream at the point of retail sale to a qualified patient.
Other interpretations suggest the federal framework requires segregation much earlier — potentially at cultivation, manufacturing, or distribution.
The rule itself does not fully resolve that issue, and DEA has not provided guidance. Given these unknowns, California operators considering federal registration should carefully evaluate their business structure, priorities, and risk appetite before applying for federal registration.
A. Should California Operators Pursue DEA Registration? Key Strategic Considerations
Federal registration may create significant opportunities for certain California cannabis operators, but registration is not necessarily the right path for every business. Whether pursuing registration makes sense will depend on a variety of legal, operational, and business considerations, including the operator’s license type, growth objectives, compliance history, and long-term strategic plans.
Businesses evaluating registration may wish to consider:
- License Type and Business Model. Registration pathways and evaluation criteria are more nuanced for some segments of the supply chain. For example, the potential benefits and challenges of registration can differ significantly depending on whether the operator is a retailer, distributor, manufacturer, cultivator, testing laboratory, or vertically integrated business.
- State and Local Compliance History. Federal law requires consideration of compliance with applicable state and local laws when evaluating certain registration applications. Operators with significant regulatory violations, disciplinary actions, permit disputes, or unresolved compliance issues should carefully evaluate how those matters may affect the registration process.
- Prior Enforcement Activity and Diversion Concerns. Past enforcement actions—particularly matters involving alleged diversion, inventory discrepancies, unauthorized transfers, recordkeeping failures, or similar compliance concerns—may warrant additional analysis before pursuing registration.
- Medical and Adult-Use Operations. Businesses currently operating integrated medical and adult-use models should evaluate whether future federal requirements could require greater operational separation of inventory, personnel, facilities, ownership structures, or business functions.
- Growth Strategy and Market Positioning. Registration may be more attractive to operators pursuing multi-state expansion, institutional investment, pharmaceutical partnerships, interstate commerce opportunities, or participation in a federally recognized medical marijuana market. Other operators may determine that the costs and uncertainties currently outweigh the potential benefits.
- Disclosure and Compliance Obligations. Registration may require substantial disclosures regarding ownership, operations, regulatory history, and business activities. Operators should understand the scope of those obligations and the ongoing compliance commitments associated with participation in the federal framework.
- Regulatory Uncertainty. Significant questions remain regarding implementation, enforcement priorities, registration standards, and the interaction between federal registration requirements and California’s dual-use market. Businesses should carefully evaluate whether immediate registration or a wait-and-see approach best aligns with their risk tolerance and operational objectives.
Ultimately, registration should be viewed not simply as a regulatory application, but as a strategic business decision. For some operators, participation in the emerging federal medical marijuana framework may create meaningful growth opportunities. For others, maintaining operational flexibility while monitoring further regulatory developments may be the more prudent course.
B. DCC Exploring Pathways to Support California Operators Applying for Federal Registration
If the current framework holds, many operators may ultimately need substantial separation between medical and adult-use operations.
That could include:
- separate inventory tracking,
- separate SOPs,
- separate entities,
- separate facilities,
- separate ownership structures,
- or separate premises.
The California Department of Cannabis Control (“DCC”) has already begun exploring pathways to align the California regulatory system with the federal framework and support California licensees interested in federal registration.
Specifically, DCC streamlined the process for licensees to add an M-designation, or change its A-designation to an M-designation. This can be done by submitting a Form 27: Notifications and Requests to Modify a License, and local authorization is no longer required.
Additionally, DCC adopted emergency regulations allowing licensees authorized to engage in retail activities to modify its license, such that the A- and M-designations are separated into two distinct licenses.
Notably, DCC’s emergency rulemaking suggests California regulators recognize that federal registration may ultimately require greater separation between medical and adult-use operations. While the long-term structure remains uncertain, the rule changes may provide operators with an early mechanism to prepare for a more segregated federal medical framework.
That may become increasingly important for businesses seeking:
- 280E relief,
- Institutional investment,
- Interstate commerce participation,
- Export authority,
- Or broader federal compliance protections.
III. Interstate Commerce: Potentially Transformative, Process Unknown
One of the most interesting aspects of 21 CFR 1301.13(k) is that it repeatedly references transactions between “registered” entities without expressly limiting those transactions to a single state.
Read literally, the framework potentially contemplates interstate transactions between federally registered medical marijuana businesses.
In theory, a federally registered California cultivator could potentially sell to a federally registered distributor, for example, in another state.
However, enormous unanswered questions remain, including:
- State import/export restrictions,
- Dormant Commerce Clause issues,
- DEA transportation rules,
- FDA/Food Drug & Cosmetic Act (“FDCA”) concerns,
- and federal treaty obligations.
At this stage, interstate medical cannabis should be viewed as a developing possibility — not a settled operational right.
A. Export Licensing and the Single Convention
Export raises even greater complexity.
One of the most important concepts operators must understand is that federal cannabis scheduling has always been heavily influenced by international treaty obligations — particularly the Single Convention on Narcotic Drugs.
The United States remains bound by international treaty obligations requiring federal control and monitoring of narcotics distribution, manufacturing, and export activity.
Historically, the federal government repeatedly cited the Single Convention as one of the principal barriers to broader cannabis legalization and descheduling.
That matters because even after rescheduling:
- DEA still must administer cannabis in a manner consistent with treaty obligations;
- International movement of cannabis will likely remain heavily monitored;
- And export activity will almost certainly receive heightened scrutiny compared to ordinary domestic activity.
Export also introduces an additional layer of regulatory complexity beyond DEA registration itself.
Many international medical cannabis markets — particularly Europe and Germany — operate under pharmaceutical-style manufacturing and quality standards, including EU-GMP (European Union Good Manufacturing Practice) requirements relating to:
- Cultivation controls,
- Manufacturing procedures,
- Quality assurance,
- Batch consistency,
- Testing,
- Documentation,
- And chain-of-custody protocols.
As a result, DEA registration alone may not be sufficient to participate meaningfully in international medical cannabis markets.
Operators pursuing export opportunities may ultimately need to navigate:
- DEA registration requirements,
- State medical licensure,
- Treaty compliance obligations,
- Importing-country pharmaceutical regulations,
- Transportation/export controls,
- And GMP or EU-GMP standards simultaneously.
For California operators, this becomes especially significant because export activity likely pushes cannabis operations closer to a federally supervised medical/pharmaceutical model than the traditional state adult-use cannabis framework.
As a result, operational segregation becomes increasingly important.
Businesses pursuing export opportunities should strongly consider:
- Separate medical operational structures,
- Separate inventory systems,
- Separate entities or premises where feasible,
- And minimizing commingling between export-related medical activity and adult-use operations.
At this stage, the federal export framework remains underdeveloped, and many practical implementation questions remain unresolved. Operators should therefore approach export planning carefully and expect significant additional regulation, guidance, and oversight to develop over time.
IV. DEA Forms and Ongoing Regulatory Uncertainty
Another major issue is that the DEA registration process itself is still evolving, and the lack of federal guidance regarding how applicant information will be used creates potential risks.
Certain questions create obvious legal tension, including inquiries regarding:
- Prior handling of controlled substances without DEA registration; and
- Ongoing recreational marijuana activity.
An affirmative response to these questions could implicate federal criminal liabilities. Accordingly, applicants should carefully review their business structure and risk profile before submitting a federal registration application.
Additionally, while DEA created an application form and portal for dispensary applicants, no application forms have been created to-date for non-retail registration. Prior to implementation of the final rule, non-retail applications used DEA Form 225 — but this form was not designed for modern state-licensed cannabis businesses under the new federal framework.
DEA has since indicated that new cannabis-specific forms may be forthcoming for cultivation, manufacturing, distribution, and laboratory testing activities. In the meantime, DEA advised that non-retail applicants may file using the historical Form 225.
However, because the non-retail application process has not been updated to reflect modern state-licensed businesses applying for registration under the new federal framework, applicants should be prepared to comply with potential supplemental information requests from DEA as part of the application review process.
A. Ongoing Litigation and Upcoming DEA Hearings
Another important point operators should understand is that the rescheduling framework is not fully settled.
Multiple lawsuits and administrative challenges seeking to overturn the final order’s federal cannabis rescheduling have already been initiated, including challenges from prohibition-oriented organizations such as Smart Approaches to Marijuana (SAM) and affiliated parties.
The arguments generally assert that the federal government acted unlawfully by issuing the final order, based on:
- Alleged violations of the Controlled Substances Act;
- Treaty obligations under the Single Convention on Narcotic Drugs;
- Administrative Procedure Act (“APA”) challenges; and
- Disputes regarding accepted medical use findings.
If the courts agree with the petitioners that the final rule was issued unlawfully, the entire federal medical framework may be overturned.
At the same time, DEA administrative hearings considering whether adult-use should likewise be moved to Schedule III are scheduled to commence in late June 2026. If the hearings result in adult-use rescheduling, the initial analysis regarding the medical-only will likely change. However, how adult-use rescheduling may be implemented in comparison to the current medical framework under the final order remains unknown at this time.
Importantly, these hearings are not merely symbolic or political proceedings about whether adult-use marijuana should be moved to Schedule III. They are likely to play a significant role in shaping how DEA ultimately interprets and operationalizes the new medical marijuana framework in practice.
In many respects, the April 2026 rule established the structure of a federally recognized medical marijuana system. The upcoming hearings, however, may substantially influence how rigidly or flexibly that structure is ultimately implemented and enforced.
Issues likely to be affected include:
- Supply-chain segregation requirements;
- Interstate commerce treatment;
- Transportation and transfer rules;
- Registration mechanics and disclosures;
- Operational expectations for dual-use businesses;
- And broader enforcement posture.
The hearings will also help develop the administrative and factual record supporting the framework, which may influence future litigation, federal guidance, and long-term regulatory interpretation.
For California operators, this is particularly important because the state’s integrated adult-use and medical infrastructure creates operational realities not fully addressed by the current rule text. Many of the most important practical questions — including how strictly DEA expects medical and adult-use activities to be separated — remain unresolved.
The evolving federal marijuana framework may eventually transform the national cannabis market, including:
- Interstate commerce,
- Tax treatment,
- Institutional investment,
- Medical cannabis regulation,
- And national cannabis markets.
But right now, the framework is still incomplete. Many unknowns persist regarding the implementation of the medical-only federal framework, and the entire federal framework is subject to substantial change pending outcomes of the ongoing litigation and administrative hearing processes.
For California operators especially, the key challenge right now is understanding how to operate inside a federally recognized medical system while simultaneously navigating an existing adult-use market that remains federally prohibited.
That requires careful planning, operational strategy, and individualized legal analysis — not one-size-fits-all assumptions.
Before filing, we are advising clients to:
- Evaluate whether License contains existing M-designations
- Identify where medical and adult-use inventory, personnel, premises, and operating procedures are currently commingled.
- Review supply-chain relationships to determine whether counterparties are likely to pursue federal registration.
- Assess whether ownership, disciplinary history, or prior enforcement matters could affect registration eligibility.
- Review recordkeeping, security, and compliance systems against federal controlled-substance standards.
- Monitor DEA registration guidance, application forms, and upcoming hearing developments.
Given our experience through California’s local and statewide cannabis rollout, we fully expect additional rules, regulatory guidance, and enforcement insights to evolve significantly. Our office closely monitors and engages with regulatory agencies – including the DEA – to provide clients with the most up to date and informed guidance available. Interested applicants should prioritize retaining trusted counsel to partner with as the landscape continues to evolve.
Navigating Federal Cannabis Rescheduling in California’s Dual-Use Market
For California cannabis operators, federal rescheduling may create significant opportunities involving medical cannabis operations, interstate commerce, tax treatment, investment, and federal recognition. At the same time, it raises complex regulatory and operational questions that many businesses are only beginning to evaluate. Operators should not assume that rescheduling automatically means legalization, unrestricted interstate commerce, or simplified compliance. Instead, this evolving landscape requires careful operational planning, strategic decision-making, and a clear understanding of where federal and California regulatory frameworks may align, diverge, or directly conflict.
At Manzuri Law, our attorneys have worked alongside California’s cannabis industry since the earliest stages of legalization and understand how quickly regulatory frameworks can shift. We are actively advising cannabis businesses on DEA registration strategy, medical and adult-use operational segregation, supply-chain planning, interstate commerce concerns, export considerations, federal compliance exposure, and evolving rescheduling implementation.
If your business is evaluating how these federal developments may affect your operations, now is the time to begin planning carefully and strategically. Contact our team today to discuss how we can help protect your business, preserve optionality, and position your company for the next phase of cannabis regulation.